MX9706143A - Formulacion transdermica. - Google Patents

Formulacion transdermica.

Info

Publication number
MX9706143A
MX9706143A MX9706143A MX9706143A MX9706143A MX 9706143 A MX9706143 A MX 9706143A MX 9706143 A MX9706143 A MX 9706143A MX 9706143 A MX9706143 A MX 9706143A MX 9706143 A MX9706143 A MX 9706143A
Authority
MX
Mexico
Prior art keywords
transdermal formulation
butylthio
thiadiazol
azabicyclo
transdermal
Prior art date
Application number
MX9706143A
Other languages
English (en)
Other versions
MXPA97006143A (es
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Lisa Ann Shipley
Kirti Himatlal Valia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9706143A publication Critical patent/MX9706143A/es
Publication of MXPA97006143A publication Critical patent/MXPA97006143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona un método para la preparacion de una condicion asociada con la modulacion de los receptores muscarínicos, utilizando una formulacion transdérmica de 3-[4-(butiltio)-1,2,5-tiadiazol-3-il]-1-azabiciclo [2.2.2]octano. La invencion proporciona las formulaciones de parches transdérmicos deseadas de 3-[4-(butiltio)-1,2,5-tiadiazol-3-il]-1-azabiciclo [2.2.2]octano.
MXPA/A/1997/006143A 1995-02-17 1997-08-12 Formulacion transdermica MXPA97006143A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39044595A 1995-02-17 1995-02-17
US390445 1995-02-17
US48101695A 1995-06-07 1995-06-07
US481016 1995-06-07
PCT/US1996/001371 WO1996025154A1 (en) 1995-02-17 1996-02-01 Transdermal formulation

Publications (2)

Publication Number Publication Date
MX9706143A true MX9706143A (es) 1997-11-29
MXPA97006143A MXPA97006143A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
DE69614419T2 (de) 2002-05-23
CZ255097A3 (en) 1997-12-17
BR9607722A (pt) 1998-07-14
TR199700799T1 (xx) 1998-02-21
PE17897A1 (es) 1997-06-12
CO4700408A1 (es) 1998-12-29
CA2212874A1 (en) 1996-08-22
JPH11505513A (ja) 1999-05-21
ES2159683T3 (es) 2001-10-16
WO1996025154A1 (en) 1996-08-22
HUP9802070A2 (hu) 1999-02-01
US5858393A (en) 1999-01-12
CN1181007A (zh) 1998-05-06
FI973362A0 (fi) 1997-08-15
AU4774296A (en) 1996-09-04
AR002027A1 (es) 1998-01-07
EP0727208A1 (en) 1996-08-21
NZ302147A (en) 1998-10-28
YU6196A (sh) 1998-09-18
NO973715D0 (no) 1997-08-12
NO973715L (no) 1997-08-12
EP0727208B1 (en) 2001-08-16
HUP9802070A3 (en) 2000-09-28
FI973362A (fi) 1997-08-15
DE69614419D1 (de) 2001-09-20
KR19980702239A (ko) 1998-07-15
AU700023B2 (en) 1998-12-17
IL116997A0 (en) 1996-06-18

Similar Documents

Publication Publication Date Title
NZ302147A (en) Transdermal patch formulation containing 3-[4-(butylthio)-1,2,5-thiazol-3-yl]azabicyclo[2.2.2]octane
EP0984004A3 (en) Trisubstituted-piperidinyl-N-alkylcarboxylates as opioid antagonists
MY113036A (en) Oral liquid formulation containing paroxetine
AU2595392A (en) Substitued 4-alkoxypyrimidines, a process for preparing the same, agents containing the same and their use as pest control agents
NZ307596A (en) 3-cyano-3-(pyridyl, phenyl, pyrazinyl or pyridazinyl)-8-azabicyclo[3.2.1]octane derivatives and pesticidal compositions
AU615129B2 (en) Dispensing devices powered by hydrogel
MX9700696A (es) Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
AU3876593A (en) Process for the preparation of polyolefin waxes
AU1505788A (en) A method and a composition for treating neurological diseases such as migraine, by influencing the nerve cells
AU6488294A (en) Hypoglycemic agents
AU5763598A (en) Injection device
AU1388092A (en) Piperidine derivatives
EP1181935A3 (en) Agent for treating mental disorders associated with cerebrovascular disorders
MX204497B (en) Liquid amine composition for emulsifiers for bitumen
GR3025771T3 (en) Stabilizing mixture for compounds having photochromatic activity
AU3903897A (en) Processes for preparing indeno{1,2-e}{1,3,4}oxadiazine-dicarboxylates
AU592006B2 (en) Ophthalmic composition for treating nerve degeneration
ZA943904B (en) Heterocyclic chemistry
EP0821957A3 (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
AU3101597A (en) Tool for placing an explosive cartridge under the soil surface
AU6705590A (en) Pyridylcarbamate compounds, process for preparing the same, and biocidal composition containing the same for controlling harmful organisms
PL334569A1 (en) Substituted 4-(6-fluoro-(1h)-indol-3-yl)-1,2,3,6-tetrahydropyridine for treating the central nervous system
EP0821955A3 (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder
ECSP961661A (es) Formulaclion transdermica
NO960151L (no) Polyisocyanat-blanding